학술논문

α/Sulfono-γ-AA peptide hybrids agonist of GLP-1R with prolonged action both in vitro and in vivo
Document Type
article
Source
Acta Pharmaceutica Sinica B, Vol 13, Iss 4, Pp 1648-1659 (2023)
Subject
GLP-1
Peptidomimetics
Helical structures
Stability
Type-2 diabetes treatments
Rational design
Therapeutics. Pharmacology
RM1-950
Language
English
ISSN
2211-3835
Abstract
Peptides are increasingly important resources for biological and therapeutic development, however, their intrinsic susceptibility to proteolytic degradation represents a big hurdle. As a natural agonist for GLP-1R, glucagon-like peptide 1 (GLP-1) is of significant clinical interest for the treatment of type-2 diabetes mellitus, but its in vivo instability and short half-life have largely prevented its therapeutic application. Here, we describe the rational design of a series of α/sulfono-γ-AA peptide hybrid analogues of GLP-1 as the GLP-1R agonists. Certain GLP-1 hybrid analogues exhibited enhanced stability (t1/2 > 14 days) compared to t1/2 (